Literature DB >> 20557490

Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies.

Orlando M Gutiérrez1, Myles Wolf.   

Abstract

Hyperphosphatemia is an independent risk factor for mortality in patients on maintenance dialysis. Since phosphorus clearance by standard three times-weekly dialysis is insufficient to balance ongoing dietary phosphorus intake, strategies to prevent absorption of dietary phosphorus are essential for attenuating increased serum levels. Dietary phosphorus binders are used widely for this purpose but dietary phosphorus restriction is relatively underutilized, most likely because of the logistical complexity of instituting and monitoring a low phosphorus diet, and for fear of worsening protein-energy wasting, which itself is a potent risk factor for mortality. In this review, we propose sustainable strategies for reducing phosphorus intake while avoiding exacerbation of protein-energy wasting. The approach is based on recognition of the dissociation between protein and phosphorus content in phosphorus-rich processed foods and the varying phosphorus bioavailability in different dietary sources. Controlling serum phosphate levels is among the most challenging aspects of day-to-day dialysis care but integration of sensible dietary interventions will likely improve phosphorus control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20557490     DOI: 10.1111/j.1525-139X.2010.00750.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  14 in total

Review 1.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

2.  Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.

Authors:  Maureen A Murtaugh; Rebecca Filipowicz; Bradley C Baird; Guo Wei; Tom Greene; Srinivasan Beddhu
Journal:  Nephrol Dial Transplant       Date:  2011-08-02       Impact factor: 5.992

3.  A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

Authors:  David E Leaf; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2012-08-30       Impact factor: 8.860

4.  Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Chien-Te Lee; I-Wen Wu; Shou-Shan Chiang; Yu-Sen Peng; Kuo-Hsiung Shu; Ming-Ju Wu; Mai-Szu Wu
Journal:  J Nephrol       Date:  2014-05-20       Impact factor: 3.902

Review 5.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 6.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

7.  Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease.

Authors:  Edward J Weinman; Paul D Light; Wadi N Suki
Journal:  Am J Kidney Dis       Date:  2013-06-12       Impact factor: 8.860

Review 8.  Update on fibroblast growth factor 23 in chronic kidney disease.

Authors:  Myles Wolf
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

Review 9.  Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence.

Authors:  Adrian Covic; Anjay Rastogi
Journal:  BMC Nephrol       Date:  2013-07-18       Impact factor: 2.388

10.  The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.

Authors:  Walter G Wasser; Amnon Gil; Karl L Skorecki
Journal:  Rambam Maimonides Med J       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.